• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New Surgalign Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SRGA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRGA

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Surgalign in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for SRGA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Surgalign. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2023HC WainwrightReiterated RatingBuy$3.50Low
12/21/2022HC WainwrightInitiated CoverageBuyLow
2/14/2022Lake Street CapitalSet Target$30.00High
11/10/2021Piper SandlerLower TargetOverweight ➝ Overweight$90.00 ➝ $67.50High
9/28/2021Craig HallumDowngradeBuy ➝ Hold$45.00High
8/9/2021Lake Street CapitalLower TargetBuy$240.00 ➝ $120.00Medium
8/9/2021Cantor FitzgeraldLower TargetOverweight$150.00 ➝ $120.00Medium
8/6/2021Piper SandlerLower TargetOverweight$120.00 ➝ $90.00Medium
2/3/2021BTIG ResearchInitiated CoverageBuy$120.00High
2/2/2021Piper SandlerInitiated CoverageOverweight$120.00Low
11/30/2020Lake Street CapitalInitiated CoverageBuyLow
10/26/2020JMP SecuritiesLower TargetMarket Outperform$180.00 ➝ $150.00High
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Surgalign logo
Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spinal hardware implants and biomaterial products worldwide. It offers products for thoracolumbar procedures, including Streamline TL spinal fixation system, a system for degenerative and complex spine procedures; and Streamline MIS spinal fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine. The company also provides motion preservation systems comprising Coflex Interlaminar Stabilization device for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; HPS 2.0 Universal Fixation system, a pedicle screw system used for posterior stabilization of the thoracolumbar spine; and SImmetry SI Joint Fusion system, a minimally invasive surgical implant system to decrease opioid use, pain, and disability. In addition, it develops augmented reality and artificial intelligence digital surgery platform to enable digital spine surgery. The company markets its products through independent spine and biomaterial distributors to hospitals, ambulatory surgery centers, and healthcare providers, as well as through direct sales force. The company was incorporated in 1997 and is headquartered in Deerfield, Illinois. On June 19, 2023, Surgalign Holdings, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.76
Low: $0.18
High: $1.22

52 Week Range

Now: N/A

Volume

8,716,700 shs

Average Volume

1,437,152 shs

Market Capitalization

$1.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Surgalign?

The following Wall Street sell-side analysts have issued research reports on Surgalign in the last twelve months:
View the latest analyst ratings for SRGA.

What is the current price target for Surgalign?

0 Wall Street analysts have set twelve-month price targets for Surgalign in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Surgalign in the next year.
View the latest price targets for SRGA.

What is the current consensus analyst rating for Surgalign?

Surgalign currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SRGA.

What other companies compete with Surgalign?

How do I contact Surgalign's investor relations team?

Surgalign's physical mailing address is 520 LAKE COOK ROAD SUITE 315, DEERFIELD IL, 60015. The company's listed phone number is (224) 303-4651 and its investor relations email address is [email protected]. The official website for Surgalign is www.surgalign.com. Learn More about contacing Surgalign investor relations.